RxDoctor Payments DataLook up a doctor →

Bryce Cowgill

Acute Care · Cumming, GANPI 1770915191

Payments from drug & device makers

$15,877in general payments, 2019–2025

Across 801 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Sanofi$848
  • Harmony Biosciences LLC$781
  • Jazz Pharmaceuticals Inc.$764
  • plus $8K from 41 others

What the payments were for

  • Food & beverage$15,45497%
  • Education$4233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,877 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Medicare billing

Part B allowed, 2024
$81,875
Medicare patients
355
Services billed
1,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter644$539,868
AdempasRiociguat15$192,077
Breztri AerosphereBudesonide/Glycopyr/Formoterol176$125,829
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr163$102,893
TezspireTezepelumab-Ekko12$54,484
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$18,941
Albuterol Sulfate HfaAlbuterol Sulfate462$14,604
Combivent RespimatIpratropium/Albuterol Sulfate16$12,890
SymbicortBudesonide/Formoterol Fumarate28$9,611
Spiriva RespimatTiotropium Bromide12$9,439
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14$9,334
Breo ElliptaFluticasone/Vilanterol18$8,481
EliquisApixaban12$7,084
Dexlansoprazole DrDexlansoprazole17$6,445
Advair HfaFluticasone Propion/Salmeterol18$6,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,337$651,242825 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere$2,367$199,257230 claims
BayerAdempas$110$192,07715 claims
Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat$1,224$41,27066 claims
PfizerEliquis$45$7,08412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.

Other acute care in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →